A randomized, double-blind, multicenter noninferiority study reported that a single intra-articular injection of crosslinked hyaluronic acid (LBSA0103, Synovian) matched the clinical performance of a three-injection hyaluronic acid regimen (Synvisc) for knee osteoarthritis in Chinese patients. The trial’s primary endpoint was change in WOMAC-Likert pain score at 13 weeks. In the study of 265 patients, both groups reduced pain substantially, with mean changes of -7.33 in the LBSA0103 group versus -6.76 in the Synvisc group. Investigators confirmed noninferiority by ensuring the upper bound of the 97.5% confidence interval stayed below the prespecified 1.6-point margin. For product developers and clinicians, the single-dose finding is operationally relevant: fewer injections can reduce procedure burden while maintaining efficacy and safety, which can influence payer and clinic adoption decisions.